All News

A#2528 Hes1/Piezo1 Pathway - role in osteocyte response to mechanical stimulus Yoda1 - Piezo1 agonist shown to help fx healing in mice Piezo1 decrease in GIOP Basic sci research shows activation of pathway promotes mechanical stress response, decr GIOP #ACR24 @RheumNow

Eric Dein ericdeinmd ( View Tweet)

Does adding a Clofutriben (HSD-1 inhibitor) w/ prednisone minimize the risks of steroid toxicities in #PMR patients? VS placebo, PMR patients who received Clofutriben + Prednisone had substantial reductions in bone, lipid, and glycemic control parameters @RheumNow #ACR24

Akhil Sood MD AkhilSoodMD ( View Tweet)

Late-Breaking Abstract L07 The CLASS Project introduces new global classification criteria for Anti-Synthetase Syndrome (ASSD). Using the gold standard dataset, the key findings were: ✅ Definite ASSD: Sensitivity 94.3%, Specificity 99.7% ✅ Probable ASSD: Sensitivity 97.5%,… https://t.co/PtciIMTSsu https://t.co/jvJv2VNvHx

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
The 🫀is muscle‼️ 💥From the maestro herself @JuliePaikMD underscores why cardiac involvement in myositis can't be overlooked. 🔥Crucial insights with major implications for patient care and outcomes #acr24 @RheumNow @HopkinsMedicine @jhrheumatology https://t.co/mw6BvkdF2w

Links:

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)

Does vasculitis flare with checkpoint inhibitors? @MDAndersonNews experience: 17 stable pts 4 pts flared - all able to be controlled (i.e. 13 didn't flare) Encouragement that stable vasculitis pts that need ICI should get them! #ACR24 ABST1986 @RheumNow https://t.co/jO4w3HWBMd

Links:

David Liew drdavidliew ( View Tweet)
A#2529 Disparities in JIA Outcome documentation, best practices, access to at-risk pts, agency and access - outcomes initially appeared to worsen - reflection of better documentation Improvement driven by pt global scores Disparity gap closed by 17% #ACR24 @RheumNow https://t.co/oOxs0jIvBK

Links:

Eric Dein ericdeinmd ( View Tweet)
Here’s my take on A#1743 and 1745 on @RheumNow #ACR24 coverage https://t.co/PcRn8Hb4PY https://t.co/2vDyyJUp6W

Links:

Eric Dein ericdeinmd ( View Tweet)

Risks for HCQ cardiotoxicity: 👉>5 yrs use 👉>5 mg/kg/d (cumulative dose >500,000 mg) 👉CKD 👉use NSAID 👉preexisting heart dz 👉presence of ocular, derm, SkM toxicity - Dr M Garschik #ACR24 @rheumnow https://t.co/LFobgls4jm

Links:

TheDaoIndex KDAO2011 ( View Tweet)
A#2530 ANA reactive CD4 cells: elevated B cell help activation in SjD Unique autoreactive T cell cluster in SSc shows CD4+ TRAIL+ IFN type I - unique to SSc Leads to decrease activation of APCs, decrease CD4 T effector fxn @RheumNow #ACR24 https://t.co/4JnA3SpVM8

Links:

Eric Dein ericdeinmd ( View Tweet)

#2259 💊 Anti-Obesity Meds in RA 📊 152 RA patients on semaglutide/tirzepatide 🔑 Findings 💥Significant ⬇️weight, BMI, ESR, CRP, lipids, pain VAS 💥Improved CVD risk ⛔ 15% GI side effects, 27% discontinued 🔎Study of impact on RA outcomes needed #ACR24 @RheumNow #ACRBest https://t.co/6LCTZl5173

Links:

Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Cool study investigating differences in nailfold capillaroscopy, jives w/my clinical experience Compared to SLE, pts with DM 🔼nailfold changes, 🔼 loop dilation, 🔼hemorrhages #ACR24 @rheumnow Abstr#2404 https://t.co/8N7KNRZet8

Links:

Mike Putman EBRheum ( View Tweet)
Dr. @karen_kc123 discusses the results of the VITAL study. - Long term use of Vit D3 2000IU was safe and decreased the incidence of all autoimmune dses by 22%. - It took a while to work but the effect dissipates once discontinued. @RheumNow #ACR24 @rheumarhyme https://t.co/mnwRsdZ06N

Links:

sheila RHEUMarampa ( View Tweet)
Will be covering some TAK pearls and pitfalls from today’s session! Renal dz stratified by location of vessel inflammation: - TAK = proximal (off aorta) - FMD = mid-section, beading - PAN = distal arterial branches @RheumNow #ACR24 https://t.co/zu6qJ6DXcF

Links:

Brian Jaros, MD Dr_Brian_MD ( View Tweet)
A call for ANA stewardship? Abstract 1931: Educating clinicians on wise ANA ordering via EMR Alert plus removing the comprehensive ANA panel --> - ↓ ANA testing (outpatient 15.9%→7.4%, inpatient 25.5%→6.4%) ↓ costs ($440k→$130k) #ACR24 @RheumNow

Akhil Sood MD AkhilSoodMD ( View Tweet)

Study of 25K+ patients using TrinetX on immune checkpoint inhibitors shows no significant mortality difference between those with pre-existing autoimmune disease (AID) and those without. Mortality rates: AID: 39.8% Non-AID: 40.2% Large-scale evidence supports ICIs in AID… https://t.co/BI5jK9jsoM

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

A#2531 @AlisaMueller CRISPR deletion of fibroblasts, gave cytokine activation to mimic inflamm Are there gene depletions that affect inflamm pathways? 👉SIX1 reduces inflamm potentiation 👉NFIL3 deletion promotes inflamm, degradation @RheumNow #ACR24 https://t.co/Nqghb5UaBR

Links:

Eric Dein ericdeinmd ( View Tweet)
A#2532 Pre-existing AID for immunoRx? Excluded from trials 4 prior studies showed no diff in mortality w AID Propensity-matched cohort study Followed median 250 days Hazard ratio: 1.07 (unmatched), 0.97 (matched) - no diff. Mortality about 40% in grps @RheumNow #ACR24 https://t.co/zyVCPts6s6

Links:

Eric Dein ericdeinmd ( View Tweet)
#ACR24 Guidelines #LupusNephritis for refractory dz @RheumNow https://t.co/LlSixkggKK

Links:

TheDaoIndex KDAO2011 ( View Tweet)
Imaging in TAK Diagnosis @KQuinnRheum @RheumNow ⭐ Take homes ⭐ 👉location of renal artery stenosis (RAS) key to making Dx with proximal RAS in TAK 👉FDG PET -focal uptake in TAK vs diffuse in GCA 👉MRI good surrogate for disease activity where PET unavailable #ACR24 https://t.co/UWxTAZScIt

Links:

Patricia Harkins DrTrishHarkins ( View Tweet)
Mental health, sex, and comorbidities are key factors in determining recalcitrant psoriatic arthritis (PsA). Key findings: - 21.7% of patients required ≥4 biologic/targeted synthetic DMARDs. - Female patients and those with depression were more likely to be recalcitrant. - No… https://t.co/I9YYoRnLwh https://t.co/VtnPceVLOZ

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
×